[HTML][HTML] Yap1 activation enables bypass of oncogenic Kras addiction in pancreatic cancer

A Kapoor, W Yao, H Ying, S Hua, A Liewen, Q Wang… - Cell, 2014 - cell.com
A Kapoor, W Yao, H Ying, S Hua, A Liewen, Q Wang, Y Zhong, CJ Wu, A Sadanandam
Cell, 2014cell.com
Activating mutations in KRAS are among the most frequent events in diverse human
carcinomas and are particularly prominent in human pancreatic ductal adenocarcinoma
(PDAC). An inducible Kras G12D-driven mouse model of PDAC has established a critical
role for sustained Kras G12D expression in tumor maintenance, providing a model to
determine the potential for and the underlying mechanisms of Kras G12D–independent
PDAC recurrence. Here, we show that some tumors undergo spontaneous relapse and are …
Summary
Activating mutations in KRAS are among the most frequent events in diverse human carcinomas and are particularly prominent in human pancreatic ductal adenocarcinoma (PDAC). An inducible KrasG12D-driven mouse model of PDAC has established a critical role for sustained KrasG12D expression in tumor maintenance, providing a model to determine the potential for and the underlying mechanisms of KrasG12D–independent PDAC recurrence. Here, we show that some tumors undergo spontaneous relapse and are devoid of KrasG12D expression and downstream canonical MAPK signaling and instead acquire amplification and overexpression of the transcriptional coactivator Yap1. Functional studies established the role of Yap1 and the transcriptional factor Tead2 in driving KrasG12D-independent tumor maintenance. The Yap1/Tead2 complex acts cooperatively with E2F transcription factors to activate a cell cycle and DNA replication program. Our studies, along with corroborating evidence from human PDAC models, portend a novel mechanism of escape from oncogenic Kras addiction in PDAC.
cell.com